What is known and objective: Extracorporeal membrane oxygenation (ECMO) is a life-saving system used for critically ill patients with cardiac and/or respiratory failure.
| WHAT IS KNOWN AND OBJECTIVE
Extracorporeal membrane oxygenation (ECMO) is a life support system used as a bridge to recovery for patients with severe cardiorespiratory failure. 1 It is used for various clinical conditions, including cardiac sur-
gery (eg open-heart surgery), heart transplant and severe pulmonary insufficiency. 2, 3 Depending on the patient's status, venovenous (VV) or venoarterial (VA) ECMO is used. VV ECMO extracts blood from a vein, provides oxygen to the blood through an oxygenator and pushes the blood back into the large central veins or right atrium. It is used for patients who have an insufficient oxygen supply owing to the loss of lung function. Similarly, VA ECMO pushes blood back into the aorta and is used when patients have a loss of both heart and lung function. 
ECMO was first used for an adult patient with respiratory failure in
1972. 4 In 1975, successful ECMO in a neonatal patient was reported. 5 The clinical use of ECMO has increased rapidly since the H1N1 influenza pandemic in 2009. 6, 7 In addition, the benefit of ECMO was suggested in the Conventional Ventilator or ECMO for Severe Adult
Respiratory Failure (CESAR) trial. This trial included adult patients (18- 65 years) who had severe, but potentially reversible respiratory failure. The 6-month survival rate without severe disability was higher in patients treated with ECMO than in patients who received conventional ventilation management. 8 However, ECMO was associated with significant risks, including patient-related (eg extremity ischaemia and haemorrhage) or circuit-related (eg thrombus formation, pump failure and oxygenator failure) risks. 9 Because the number of patients receiving ECMO has been increasing, the effective doses of concomitant drugs have become an important issue.
Paediatric studies to date have indicated that ECMO results in the sequestration of a certain amount of drugs and prevented them from reaching the body. [10] [11] [12] [13] [14] The effect of sequestration cannot be precisely predicted, but it increases the apparent volume of distribution (Vd) 1 or reduces the excretion of drugs. 15 These pharmacokinetic (PK) alterations can significantly impact the concentration of drugs, increasing the possibility of toxicity or therapeutic failure from unanticipated changes in drug concentrations, even with ordinary dosing. Despite an increase in ECMO use in the adult population, 7 studies
regarding adult patients treated with ECMO are limited and changes in the PK of drugs used during ECMO have scarcely been reviewed.
Therefore, the aims of this study were to describe the changes in the PK of antibiotic, antiviral, antituberculosis and antifungal agents in adult patients treated with ECMO and to identify factors that may alter PK profiles.
| METHODS
A literature search was performed using the PubMed and EMBASE databases with the keywords shown in Table 1 . PK studies of antiinfective drugs in ECMO patients were included: antibiotic (vancomycin, meropenem, piperacillin/tazobactam, imipenem, linezolid, azithromycin, amikacin), antiviral (oseltamivir), antituberculosis (rifampin, ethambutol) and antifungal agents (voriconazole, caspofungin). In vitro, ex vivo and animal studies were excluded. As a result, one study of neonates (0-28 days of age), 3 studies of infants (29 days to 2 years of age), 2 studies of children (2 to <12 years of age), and 6 case reports, 8 PK studies and 2 review articles for adults (≥18 years of age) were included in the analysis.
contribute to PK changes for each drug. Finally, it is important to develop dosing guidelines based on PK/PD modelling studies that can be used in clinical practice.
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| RESULTS AND DISCUSSION

| General PK changes during ECMO
When patients receive ECMO, highly significant changes in drug PK can occur by interactions with the ECMO device itself, drug characteristics, pathological changes and patient characteristics. [16] [17] [18] The ECMO circuit itself may function as an additional PK compartment by sequestering drugs, increasing Vd and changing drug clearance (CL) and elimination. 19 The binding of drugs into a circuit is called sequestration, which decreases the concentration of drugs in the plasma; however, the circuit may release drugs that have attached to the device after the administration of a drug is stopped. [22] [23] [24] [25] Furthermore, the non-pulsatile flow of VA ECMO stimulates the renin-angiotensin system, which may cause an increase in the circulating volume and a decrease in elimination.
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Decreased pulmonary blood flows during VA ECMO could affect the metabolism of drugs in the lungs. 27 Finally, the baseline stability of drugs at 37°C is important owing to the potential for drug loss in the circuit.
The pathological characteristics of critical illnesses are also potential factors that can alter PK during ECMO. Capillary penetration, fluid shifts and retention, pH and plasma protein binding of drugs could be altered, all of which may lead to an increased Vd. 28 Renal dysfunction is common in ECMO patients, occurring at a frequency of <30%.
Renal dysfunction causes increased exposure of drugs excreted by the kidney. 7 Furthermore, haemodilution and renal replacement therapy (RRT) influence drug PK. Haemodilution occurs due to transfusions of blood products, blood required to prime the circuit. The impact of haemodilution is significant for drugs whose distribution is limited to the plasma and is likely inversely related to age. 20 The requirement rate of RRT during ECMO use in adults has been reported as 50% and 41% for VV and VA ECMO, respectively. 7 Predicting PK changes in patients receiving RRT during ECMO use can be complex due to variability in the type of modality used for RRT. And also, there are limited data regarding the impact of both RRT and ECMO on the PK of drugs.
The available studies have shown significant variability, suggesting the importance of therapeutic drug monitoring (TDM). One case report showed that extended dialysis in an ECMO patient effectively eliminates ethambutol, and rifampicin could also be found in the spent dialysate, despite previous reports indicating that it is not dialysable.
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In a matched cohort study with 5 patients receiving RRT and ECMO and 6 patients receiving ECMO only, variation in meropenem clearance was correlated with presence of RRT. 30 In an observational study, oseltamivir PK was compared among ECMO patients with preserved renal function, patients on both ECMO and continuous venovenous haemodiafiltration (CVVHDF) and healthy volunteers. Maximum concentrations (C max ) and areas under the plasma concentration-time curve (AUC) of oseltamivir were 4-to 5-fold higher in both ECMO and CVVHDF patients.
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Clinical data regarding alterations in PK during ECMO have primarily been obtained in studies of neonatal and infant populations.
Although this information is meaningful, the direct application of neonatal and infant data to the adult population may be inappropri- becomes detectable at 1-3 months of age and is present at 81% at 2 years of age. Similarly, CYP2C, CYP2D and CYP2E levels are lower in infants than in adults. 33 However, CYP3A, which is the most abundant (30%-40%) cytochrome, shows differences depending on the isoform.
CYP3A7 is the major CYP isoform in the liver of newborns, whereas CYP3A4 is the major CYP isoform in adult liver. 33, 34 Antifungal agents, such as itraconazole and ketoconazole, and the antituberculosis agent rifampicin are mainly metabolized by CYP3A4. Thus, the impact of ECMO on these drugs' PK change could be greater in adults than in neonates and infants because mature CYP3A4 enzyme levels are higher in adults. 33, 34 Therefore, analysing PK data for the adult population and determining the different characteristics between the paediatric and adult population are worthwhile. These analyses may provide a basis for essential dosing guidance for adult patients during ECMO.
| Clinical PK of antibiotic, antiviral, antituberculosis and antifungal agents in adults
As discussed above, ECMO can potentially change the PK of antibiotic, antiviral, antituberculosis and antifungal agents. PK information from studies of vancomycin, beta-lactams, linezolid, azithromycin, amikacin, oseltamivir, ethambutol, rifampicin, caspofungin and voriconazole is summarized in Table 2 .
| Vancomycin
Vancomycin is a first-line agent for the management of nosocomial infections caused by methicillin-resistant Staphylococcus aureus 
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or other resistant gram-positive bacteria. 35 However, vancomycin can be nephrotoxic and patients receiving ECMO are at a high risk of renal failure. 36 One prospective and 2 retrospective studies of vancomycin PK changes during ECMO in adults were reviewed (Table 2) . Previously, one prospective study in infants demonstrated a decrease in CL, an increase in Vd and a longer half-life for vancomycin during ECMO than in those not receiving ECMO.
14 Another retrospective controlled study of neonates found that only the half-life was significantly longer in neonates receiving ECMO.
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However, the results of 3 studies of the PK of vancomycin in adult patients differed from those of the paediatric studies. These studies uniformly demonstrated that there were no statistically significant differences in the Vd, CL or elimination rate constant (Ke) between ECMO patients and intensive care unit patients not receiving ECMO. [38] [39] [40] This difference in results may be explained by the difference in the contribution of priming fluid to the extracellular fluid in the body between neonates and adults (36% for a 4-kg neonate vs 15% for a 70-kg adult).
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Despite a lack of significant differences in PK in adults, there were noteworthy findings. First, the ECMO circuit loss of vancomycin was not significant because concomitant use of albumin decreased binding within the ECMO circuit. 40 Second, the mean time to reach target trough concentrations of vancomycin was significantly longer in the ECMO group than in the non-ECMO group. 38 Because vancomycin is hydrophilic and large amounts of plasma volume are replaced during ECMO, the plasma concentration of vancomycin during the initial ECMO phase might be low.
| Beta-lactam (carbapenem, piperacillin/ tazobactam) antibiotics
Beta-lactam antibiotics are generally used empirically or as targeted antibiotics against gram-negative pathogens. 41 We reviewed one case-matched control study of meropenem and piperacillin/tazobactam, one matched cohort study of meropenem and one case report of adult ECMO patients administered imipenem (Table 2 ).
There was only one previous case of an 8-month-old infant in which meropenem PK was examined during ECMO. When meropenem was administered via continuous infusion, CL was higher in the ECMO patient than the estimated value derived from healthy volunteers. 42 In a case-matched control study of adult patients, meropenem had a lower CL and Vd (125 mL/min and 0.46 L/kg, respectively) in those treated with ECMO than in those not treated with ECMO (144 mL/ min and 0.60 L/kg, respectively). 41 However, these results differ from those obtained in another matched cohort study of patients administered meropenem. In this case, CL decreased (7.9 L/h vs 11.7 L/h), but Vd increased (0.45 vs 0.41 L/kg) when ECMO was used. 30 The effects of ECMO on meropenem PK were not significant in either of these studies. In clinical situations, meropenem dosing needs to be adjusted according to renal function because it is renally cleared, and meropenem CL could increase because the drug is unstable at 37°C
and exterior circulation of blood during ECMO may cause unplanned degradation.
30,43,44
Patients administered piperacillin/tazobactam exhibited a higher CL and Vd (156 mL/min and 0.33 L/kg, respectively) in the ECMO group than in the non-ECMO group (134 mL/min and 0.31 L/kg, respectively), but the difference was not significant. 41 Finally, an imipenem study demonstrated a high variation in trough concentrations between 2 patients supported with ECMO (11.3 and 2.7 mg/L). 45 Owing to the limited number of patients, further large-scale population studies are needed to confirm the effects of ECMO and find other covariates that may alter piperacillin/tazobactam and imipenem PK.
| Linezolid
Linezolid is widely used to treat pneumonia patients who are in critical care. It has high pulmonary penetration and strong activity against Staphylococcus aureus. 46 However, only one case report evaluated linezolid pharmacokinetics in 3 adult patients during ECMO (Table 2) .
Although it did not have a control group and had a limited sample size, the study concluded that pharmacokinetic targets were not achieved using the standard dosage when the S. aureus MIC was above 1 mg/L. 
| Azithromycin
Azithromycin is a type of macrolide antibiotic with a notable clinical benefit in the treatment of community-acquired pneumonia and acute respiratory distress syndrome (ARDS). 48 Three adult patients with ARDS on ECMO were treated with azithromycin, and PK parameters were compared with previously published data from non-ECMO patients ( Table 2 ). The maximum and minimum concentrations, AUC
and clearance values were similar, but Vd in ECMO patients was lower than that in non-ECMO patients. However, the reason for the lower Vd was not clear. Overall, ECMO had no appreciable effect on the plasma concentration of azithromycin, and the azithromycin concentration at the infection site, for example at the epithelial lining fluid, should be considered a more effective predictive factor. 
| Amikacin
Amikacin has been used for many years to treat severe infections in critically ill patients. 50 We reviewed one case-control study that compared an ECMO group with matched critically ill patients not on ECMO ( Table 2 ). The results indicated there were no significant differences in amikacin peak and trough concentrations between the 2 groups. 
| Oseltamivir
Oseltamivir is an orally administered prodrug that is rapidly converted to an active metabolite, oseltamivir carboxylate. This drug was recommended for severe influenza A (H1N1) infection during the 2009 novel influenza H1N1 pandemic. 52 Previous studies of children have indicated that changes in oseltamivir PK during ECMO were not significant. 19, 53, 54 In a prospective case study of 3 children (6-15 years old), the oseltamivir dosage was doubled and CVVH was performed following the ECMO protocol. Two of 3 patients achieved high plasma concentrations for oseltamivir carboxylate with marked variance. This might be explained by higher dosing or renal impairment. However, owing to the limited sample size, a dosing recommendation could not be made. 54 An analysis of the other 6-year-old child revealed that the differences in oseltamivir and oseltamivir carboxylate concentrations between the pre-oxygenator and post-oxygenator of ECMO were small, suggesting little drug removal by the oxygenator during ECMO. 53 In one prospective population study, the PK parameters of oseltamivir carboxylate in 14 adult ECMO patients were compared with values reported in healthy volunteers. This study demonstrated a significant increase in Vss (179 vs 26 L) during ECMO ( Table 2) . 55 This might reflect the expanded circulating volume. 55 However, critical illnesses, such as oedema, capillary leak syndrome, third spacing and large volumes of blood products administered to patients during ECMO, could also cause expansion of the Vd. 56 The mean CL of oseltamivir carboxylate was significantly decreased in ECMO patients because oseltamivir carboxylate is primarily eliminated renally, 57 and ECMO patients have substantially decreased renal function compared to that of healthy volunteers. 55 Furthermore, they often require CVVHDF, which results in drug accumulation. 31 Patients on both ECMO and CVVHDF showed a higher C max and AUC than those of patients who were on ECMO alone. 31 When pre-and post-ECMO oxygenator membrane concentrations of oseltamivir carboxylate were compared in the same patients, there were no substantial differences.
This suggested that drug binding to oxygenators was not a relevant cause of the decreased CL. 56 The decreased CL may cause average oseltamivir carboxylate concentrations to exceed the concentrations needed to maximally inhibit the neuraminidase activity of the H1N1
virus. 55 However, oseltamivir is well tolerated and its main adverse effect is gastrointestinal distress. 58 Therefore, dose adjustment for ECMO may not be necessary, and doses should be reduced in renally impaired patients. Owing to variability in oral bioavailability, PK variability should be considered according to the route of administration. 
| Antituberculosis agents
There were 2 case reports regarding antituberculosis agents in adult ECMO patients (Table 2) . Acute respiratory distress syndrome caused by miliary tuberculosis (TB) is linked to a 60% in-hospital mortality rate. 59 Standard first-line antituberculosis agents include isoniazid, rifampicin, ethambutol and pyrazinamide. Two case reports of adult patients described different aspects of the effects of ECMO on these drugs. In one case report, PK of rifampin and ethambutol in a patient on ECMO and extended dialysis were evaluated. Because these drugs are cleared by extended dialysis, the impact of ECMO is difficult to assess. However, the removal of ethambutol and rifampicin by the ECMO membrane was not detected when pre-and post-ECMO filter levels were measured. 29 In another case report, the plasma concentration of rifampicin was below the therapeutic level, despite the use of a higher dose (750 mg) than is recommended (600 mg). 60 This indicated that rifampicin PK were influenced by ECMO or exhibit variation among patients. Several reasons were suggested to explain the alteration in PK. First, the lipophilicity of rifampicin may have caused the drug to be sequestered in the ECMO circuit, which would have led to underexposure in the patient. Second, the patient had tuberculosisinduced inflammation, which may have increased CYP450-mediated metabolism and resulted in a subtherapeutic rifampicin levels. 60 
| Antifungal agents
The most common infectious organisms found in adult patients during ECMO are Candida species. 61 Candida infections are difficult to eradicate owing to the adherence of organisms to indwelling catheters. Therefore, the administration of the optimal dose of antifungal agents for the prevention and treatment of candidiasis is crucial during ECMO. There is only one case report regarding voriconazole and caspofungin in an adult ECMO patient ( 
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Voriconazole plasma levels remained high for a number of days after initial dosing. However, voriconazole is a time-dependent antifungal agent 63 and more studies regarding the pharmacodynamics of voriconazole are necessary to determine the optimal dosing regimen during ECMO.
There were no significant changes in the PK parameters of caspofungin because it was not sequestered in the ECMO circuit.
Caspofungin was maintained at an adequate level with standard dosing during ECMO. 62 However, in an infant, a reduced AUC, increased clearance and subtherapeutic exposure of caspofungin were observed during ECMO. 
| Considerations during TDM
The PK of vancomycin, piperacillin-tazobactam, meropenem, azithromycin, amikacin and caspofungin did not change significantly in adult patients receiving ECMO. However, there were significant changes in the PK of imipenem, oseltamivir, rifampicin and voriconazole. The trough concentrations of imipenem were highly variable, oseltamivir had a decreased CL and increased Vd and rifampicin concentrations were below therapeutic levels, even when a higherthan-standard dose was used in patients treated with ECMO.
Additionally, voriconazole exhibited high mean peak concentrations during ECMO.
| WHAT IS NEW AND CONCLUSION
Generally, it is known that the volume of distribution (Vd) increases and the drug clearance (CL) and elimination decrease during ECMO. 64 This review indicated that the PK changes for each drug did not always reflect these general trends in adult patients. The effects of ECMO on PK parameters vary depending on the individual drug, and there is not a consistent correlation between results obtained in adult and paediatric studies owing to differences in physiological characteristics, such as the amount of extracellular fluid, metabolic enzymes and water. [32] [33] [34] This review suggested which drug dosage regimens should be changed when ECMO is used in adult patients.
There were no significant differences in the PK parameters of vancomycin, piperacillin-tazobactam, meropenem, azithromycin, amikacin and caspofungin when ECMO was used in adult patients.
Conversely, there were considerable changes in the PK of imipenem, oseltamivir, rifampicin and voriconazole during ECMO. In the case of imipenem, trough concentrations were variable and it was hard to determine the exact effect of ECMO. A significantly increased
Vd and decreased CL of oseltamivir were observed during ECMO.
Higher doses of rifampicin were necessary for patients receiving In the future, large PK trials in adults on ECMO with the latest ECMO technology and appropriate control groups are needed to provide optimal dosing guidelines. A PK/PD modelling approach will be useful for determining the precise impacts of ECMO and other factors that contribute to PK changes for each drug. Finally, it is important to develop dosing guidelines based on PK/PD modelling for use in clinical practice.
